Navigation Links
Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 29th Annual Canaccord Adams Global Growth Conference. The details are as follows:

    Date:  Thursday, August 13, 2009
    Time:  10:00 a.m. Eastern
    Location: InterContinental Boston, London Room
    Speaker: Michael Narachi, Chief Executive Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010, and Empatic(TM) which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
3. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
4. Orexigen(R) Therapeutics to Present at Upcoming Meetings
5. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
6. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
7. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
11. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule cocrystal technology ... latest FDA guidance on pharmaceutical cocrystals as drug substance . The Lunch ... , The event follows the successful November 15th event that took place in Burlingame, ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... in the development of a new orally administered treatment for Alzheimer’s disease (AD), ... results of a Phase 2a clinical trial of T3D-959 in mild to moderate ...
(Date:11/30/2016)... London, UK (PRWEB) , ... November 30, 2016 , ... ... old offices on Haymarket after five years and look forward to continuing their expansion ... heart of Soho, an area which has been traditionally favoured by the creative industries, ...
(Date:11/30/2016)... ... November 30, 2016 , ... Microbial ... venture founded by Arianna Huffington, as part of the Thrive Global pop-up store. ... Kit, enabling purchasers to explore the microorganisms in their gut, collectively known as ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):